Glory Health Industry Limited (GLORY HEALTH) has approved an updated Nomination Committee Charter, effective 2 June 2026, aimed at enhancing board governance and diversity.

The revised charter mandates a Nomination Committee of at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. The committee chair will be either the board chair or an independent non-executive director, elected by the board.

Key responsibilities now include: • Annual review of board size, structure, skills mix and diversity, supported by a formal board-skills matrix. • Identification and recommendation of director candidates in line with the company’s nomination and board diversity policies. • Ongoing assessment of independent non-executive directors’ independence. • Recommendations on director appointments, re-appointments and succession planning, particularly for the board chair and chief executive officer. • Regular evaluation of directors’ time commitments and performance contribution.

Operationally, the committee must meet at least once per year, with meetings valid only if a majority of members— including at least one independent non-executive director—are present. Decisions require more than 50% affirmative votes. Written resolutions may replace physical meetings where necessary.

Compensation for committee members will be set by the board and may be paid in cash, shares or options, excluding consultancy or advisory fees. The committee is authorised to access company resources and engage external advisers, with related costs borne by the company.

The updated charter will be published on both the company’s and Hong Kong Stock Exchange websites in accordance with listing requirements.